Ruthenium(II) p-cymene complex bearing 2,2â²-dipyridylamine targets caspase 3 deficient MCF-7 breast cancer cells without disruption of antitumor immune response

Article ID	Journal	Published Year	Pages	File Type
7755018	Journal of Inorganic Biochemistry	2015	32 Pages	PDF

Abstract

Synthesis and characterization of [Ru(Î·6-p-cym)Cl{dpa(CH2)4COOEt}][PF6] (cymÂ =Â cymene; dpaÂ =Â 2,2â²-dipyridylamine; 2) as well as its antitumor activity and that of [Ru(Î·6-p-cym)Cl(dpa)][PF6] (1) is described. The most prominent activity was observed for 1 against caspase deficient MCF-7 breast cancer cells without affect to the immune cells and cytokine production.180

Keywords

FCS p-cym SW480 A253 Annexin V-FITC Melanoma cell line ConA CFSE IL-17 IFN-γ DMF IL-10 MCF-7 SRB PBS HEPES DPA Concanavalin A 2,2′-dipyridylamine 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 4-(2-Hydroxyethyl)piperazine-1-ethanesulfonic acid DMSO MTT p-Cymene Acridine orange interferon γ Interleukin 10 interleukin 17 Crystal violet Colon cancer cell line Anticancer drugs dimethylformamide Dimethyl sulfoxide Ruthenium(II)fetal calf serum Immune cells Spleen cells sulforhodamine B Cytokines cisplatin Phosphate-buffered saline Propidium iodide Pyridine carboxyfluorescein diacetate succinimidyl ester